文献速递肿瘤 PET/CT

Rosai-Dorfman病:18F-FDG PET/CT用于初始评估与随访的价值

Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up.
PubMed 文献 · Clin Nucl Med · 2020-01-01

该研究基于机构病理数据库(2001-2018年)纳入27例Rosai-Dorfman病患者,回顾109次FDG PET/CT扫描,评估其在初始疾病特征描述、随访评估和治疗计划中的作用。PET/CT在24/27例患者中识别出活动性疾病部位,在6/20例有既往CT或MRI的患者中发现解剖影像未显示的额外病灶,13/109次扫描导致治疗改变,影响41%(11/27)的患者。

要点

  • PET/CT在24/27例RDD患者中识别出活动性疾病部位。
  • 6/20例(30%)有既往CT或MRI的患者中,PET/CT发现解剖影像未显示的额外RDD病灶。
  • 13/109次PET/CT扫描导致治疗改变,影响41%(11/27)的患者。

核心结论

  • FDG PET/CT在明确RDD疾病范围和优化治疗策略方面有价值。

研究设计与样本

  • 从机构病理数据库(2001-2018年)识别接受FDG PET/CT扫描的RDD患者,扫描作为临床诊疗或临床试验的一部分进行。
  • 共回顾27例RDD患者的109次FDG PET/CT扫描,评估异常FDG摄取部位并测量SUVmax,与可获得的解剖影像(CT/MRI)比较,记录基于PET/CT改变治疗的实例。

主要发现

  • 27例患者中5例仅有淋巴结/皮肤病变,22例有结外病变,最常见于骨(n=9)和中枢神经系统(n=7)。
  • PET/CT在24/27例患者中识别出活动性疾病部位;除1例患者脑部病灶外,所有识别的骨和骨外病灶均FDG高摄取。
  • 20例有既往CT或MRI的患者中,6例(30%)PET/CT显示解剖影像未明显的额外RDD病灶(骨n=5,胸膜n=1);其中3个病灶位于CT视野外,3个在CT上未被识别。
  • 109次PET/CT扫描中13次导致管理改变,影响41%(11/27)的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of imaging in the management of Rosai-Dorfman disease (RDD), a rare non-Langerhans cell histiocytosis, is not clearly defined. We present an analysis of FDG PET/CT findings obtained for initial disease characterization, follow-up evaluation, and treatment planning for this disease. METHODS: From an institutional pathology database (2001-2018), we identified RDD patients who underwent FDG PET/CT scans either as part of clinical care or when done as part of clinical trials. For all scans, sites of abnormal FDG uptake were assessed, and SUVmax was measured. Comparison of PET/CT findings was made with anatomic (CT/MRI-based) imaging, where available. Instances of changing treatment based on PET/CT were recorded. RESULTS: We reviewed 109 FDG PET/CT scans in 27 patients with RDD. Five of 27 patients had only nodal/cutaneous disease, whereas 22 patients had extranodal disease, most commonly in bone (n = 9) and central nervous system (n = 7). PET/CT identified sites of active disease in 24 of 27 patients. All identified bone and extraskeletal lesions, except for a brain lesion in 1 patient, were FDG-avid. In 6 of 20 patients (30%) with available prior CT or MRI, PET/CT demonstrated additional RDD lesions (bones: n = 5, pleura: n = 1) that were not apparent on anatomic imaging; 3 of these lesions were outside the CT field of view, and 3 were not recognized on CT. Overall, 13 of 109 PET/CT scans led to a change in management, affecting 41% (11/27) of patients. CONCLUSION: FDG PET/CT was valuable in defining disease extent and optimizing treatment strategy in patients with RDD.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mahajan S, Nakajima R, Yabe M, et al. Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clin Nucl Med. 2020. PMID: 32349088. doi:10.1097/RLU.0000000000003014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。